Growth In Treatment Options For Patients At Orlando Health
ORLANDO - Orlando Health UF Health Cancer Center is growing and offering cancer patients exciting, new treatment options.
Leaders with Orlando Health and the West Orange Healthcare District (WOHD) broke ground on a new cancer center on the campus of Health Central Hospital in Ocoee, Florida in June.
At 30,000 square feet, the new Orlando Health UF Health Cancer Center – Ocoee will almost double the size of the existing cancer center located near the hospital campus. The new comprehensive cancer center will feature expanded chemotherapy and radiation treatment areas, medical oncology services, surgical oncology consultations, laboratory facilities, and Cancer Support Community programs. Among the advances that will available is a new cancer-fighting technology called MRIdian® that allows oncologists to see the tumor they are treating continuously during radiation therapy.
“Our new Ocoee location is greatly needed to continue to meet the growing healthcare demands of West Orange County,” said Mark Roh, M.D., president of Orlando Health UF Health Cancer Center. “We met the five-year capacity of the existing cancer center just two years after opening our doors in 2012, so this expansion will ensure residents of this community will have greater access to the most advanced cancer care.”
The new Ocoee cancer center is part of a $100-million project, $75 million of which is funded by the WOHD, to help transform Health Central Hospital into a destination medical campus and bring much-needed healthcare services to other parts of the community. The expected completion date for construction is late summer 2018.
The expansion of services into growing parts of the community allows oncologists at Orlando Health to offer advanced treatment options to a greater number of patients. Breast cancer is no exception.
New treatment options are needed for women with locally advanced or metastatic HER2-positive breast cancer.
Orlando Health is currently recruiting patients in a pivotal trial designed to evaluate a new, investigational medication for women with HER2-positive breast cancer, including patients with cancer that has spread to the brain.
The randomized pivotal study, called HER2CLIMB, will evaluate the investigational medication tucatinib in combination with approved standard treatments in patients with locally advanced or metastatic HER2-positive breast cancer, with or without brain metastases.
Patients who have been diagnosed with HER2-positive breast cancer and whose cancer has spread to other parts of their body may benefit from treatment with HER2-targeted therapies. This investigational medication is designed to inhibit the activity of HER2 and is being evaluated in combination with other approved therapies. In addition, it is important to note that HER2CLIMB is enrolling patients with HER2-positive breast cancer that has spread to the brain, a patient population that is often excluded from clinical trials.
Tucatinib is a HER2 inhibitor designed specifically to target and inhibit the growth of HER2-positive cancer cells. It is an oral medication that can be taken at home.
To be eligible for the study, women or men must have locally advanced or metastatic HER2-positive breast cancer, with or without brain metastases, and meet certain other eligibility criteria. To learn more about this trial, please contact the Breast Care Center at Orlando Health at 321-843-8370. You may also visit www.HER2CLIMB.com